ASO Visual Abstract: Cryoablation without Excision for Early Stage Breast Cancer; ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence
Fine R, Gilmore R, Tomkovich K, Dietz J, Berry M, Hernandez L, Columbus K, Seedman S, Fisher C, Han L, Manahan E, Hicks R, Vaidya R, Curcio L, Sevrukov A, Kenler A, Taback B, Chen M, Miller M, Gold L, Anglin B, Aoun H, Simmons R, Feldman S, Boolbol S. ASO Visual Abstract: Cryoablation without Excision for Early Stage Breast Cancer; ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. Annals Of Surgical Oncology 2024, 1-2. DOI: 10.1245/s10434-024-16272-y.Peer-Reviewed Original ResearchIpsilateral breast tumor recurrenceBreast tumor recurrenceEarly stage breast cancerStage breast cancerTumor recurrenceBreast cancerFollow-upCryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence
Fine R, Gilmore R, Tomkovich K, Dietz J, Berry M, Hernandez L, Columbus K, Seedman S, Fisher C, Han L, Manahan E, Hicks R, Vaidya R, Curcio L, Sevrukov A, Kenler A, Taback B, Chen M, Miller M, Gold L, Anglin B, Aoun H, Simmons R, Feldman S, Boolbol S. Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. Annals Of Surgical Oncology 2024, 31: 7273-7283. PMID: 39283572, PMCID: PMC11452421, DOI: 10.1245/s10434-024-16181-0.Peer-Reviewed Original ResearchIpsilateral breast tumor recurrenceEarly-stage breast cancerBreast tumor recurrenceTumor recurrenceAdverse eventsBreast cancerEpidermal growth factor receptor 2 (HER2)-negativeHuman epidermal growth factor receptor 2 (HER2)-negativeIpsilateral breast tumor recurrence ratesHormone receptor (HR)-positivePatients meeting eligibilityDevice-related adverse eventsNon-operative treatment optionsHistological grade 1Institutional review board approvalPotential surgical risksEfficacy of cryoablationInvasive ductal carcinomaAlternative to surgeryLow-risk patientsPrimary study endpointFollow-up periodMinimally invasive procedureQuality-of-life scoresReview board approval